Ultragenyx Pharmaceutical Inc. (RARE) Financials
Annual revenue, profitability and per-share results for Ultragenyx Pharmaceutical Inc., as reported in SEC filings.
Revenue • FY2025
$673M
▲ 20.1%YoY
Net income • FY2025
-$575M
▼ 1.0%YoY
Diluted EPS • FY2025
-$5.83
▲ 7.3%YoY
Annual income statement
| Period | Revenue | Net income | Gross profit | Dil. EPS | Free cash flow | Op. margin | Rev. growth |
|---|---|---|---|---|---|---|---|
| FY2025 | $673M | -$575M | — | -$5.83 | -$472M | -79.5% | +20.1% |
| FY2024 | $560.23M | -$569.18M | — | -$6.29 | -$421.68M | -95.7% | +29.0% |
| FY2023 | $434.25M | -$606.64M | — | -$8.25 | -$519.07M | -131.1% | +19.5% |
| FY2022 | $363.33M | -$707.42M | — | -$10.12 | -$496.59M | -178.6% | +3.4% |
Figures as reported in Ultragenyx Pharmaceutical Inc.'s 10-K filings on SEC EDGAR. Fiscal years may differ from calendar years.
Never miss a RARE filing.
Get an email when RARE files its next 8-K, Form 4, 10-K or 10-Q with the SEC. Free, no account needed.
Free foreverNo account requiredOne-click unsubscribe
Source: SEC EDGAR.